Site-specific incorporation of phosphoserine into proteins in Escherichia coli
US-9090928-B2 · Jul 28, 2015 · US
US9464288B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9464288-B2 |
| Application number | US-201214131382-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2012 |
| Priority date | Jul 11, 2011 |
| Publication date | Oct 11, 2016 |
| Grant date | Oct 11, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Non-naturally occurring tRNA Sec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNA Sec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNA Sec a recombinant expression system, such as E. coli , with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNA Sec .
Opening claim text (preview).
We claim: 1. A non-naturally occurring tRNA Sec comprising a nucleic acid sequence according to SEQ ID NO: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, or 58. 2. An isolated nucleic acid comprising a nucleic acid sequence encoding a non-naturally occurring tRNA Sec , wherein the non-naturally occurring tRNA Sec is recognized by SerRS and by EF-Tu, or variants thereof, and when aminoacylated with serine the Ser-tRNA (1) is a substrate for SelA or a variant thereof; or (2) is a substrate for PSTK and when aminoacylated with phosphorylated serine the Sep-tRNA serves as a substrate for SepSecS or a variant thereof, wherein the non-naturally occurring tRNA comprises a nucleic acid sequence according to SEQ ID NO: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, or 58. 3. The isolated nucleic acid of claim 2 further comprising a heterologous expression control sequence. 4. An expression vector comprising the isolated nucleic acid of claim 3 . 5. A host cell comprising the isolated nucleic acid of claim 2 . 6. The host cell of claim 5 wherein the host cell is a prokaryote, archaeon, or eukaryote. 7. The host cell of claim 6 wherein the prokaryotic cell is E. coli. 8. The host cell of claim 7 wherein the endogenous E. coli genes encoding selA, selB, and selC, or combinations thereof have been deleted or mutated to reduce or prevent expression of SelA, SelB, or SelC protein. 9. The host cell of claim 5 wherein the host cell expresses one or more of the proteins selected from the group consisting of SerRS, EF-Tu, SelA, or PSTK and SepSecS. 10. The host cell of claim 5 wherein the host cell expresses SerRS, EF-Tu, and SelA. 11. The host cell of claim 5 wherein the host cell expresses SerRS, EF-Tu, PSTK and SepSecS. 12. The host cell of claim 11 wherein the PSTK is a M. maripaludis PSTK or a variant thereof. 13. The host cell of claim 11 wherein the SepSecS is a M. jannaschii SepSecS or a variant thereof. 14. The non-naturally occurring tRNASec of claim 1 , wherein when aminoacylated with selenocysteine the non-naturally occurring tRNASec inserts a selenocysteine into a nascent peptide chain during translation without the requirement of a SECIS in the mRNA encoding the peptide, in the absence of SelB, or a combination thereof. 15. The isolated nucleic acid of claim 2 , wherein when aminoacylated with selenocysteine the non-naturally occurring tRNA Sec inserts, a selenocysteine into a nascent peptide chain during translation without the requirement of a SECIS in the mRNA encoding the peptide, in the absence of SelB, or a combination thereof. 16. The non-naturally occurring tRNA Sec of claim 1 , wherein the tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 17. The isolated nucleic acid of claim 2 wherein the non-naturally occurring tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 18. The host cell of claim 5 wherein the non-naturally occurring tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 19. The host cell of claim 5 wherein the nucleic acid is integrated into the host cell's genome.
acting on the aldehyde or oxo group of donors (1.2) · CPC title
L-Seryl-tRNA(Sec) selenium transferase (2.9.1.1) · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
Methyltransferases (general) (2.1.1.) · CPC title
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.